• ABOUT US
  • SCIENCE
  • FACILITY
  • BUSINESS
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • BUSINESS
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[이투데이] 1회 투약으로 완치 기대⋯‘기적의 항암제’ 국내 최초 산실을 가다

2026/06/23

1회 투약으로 완치 기대⋯‘기적의 항암제’ 국내 최초 산실을 가다 – 이투데이

Prev[이투데이] “16일 만에 맞춤형 치료제 공급⋯글로벌 CAR-T 넘어선다”
Next큐로셀 ‘국내 개발 제42호 신약’ 림카토, 제6차 심평원 암질심 통과… 하반기 출시·매출 가속도
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • BUSINESS
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • BUSINESS
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.